What Sodium Thiosulfate Treats: Main Uses and Benefits

Sodium thiosulfate is considered relevant in clinical settings that involve acute or disruptive symptom patterns. In emergency toxicology, it is used to assist in detoxification to counteract the severe systemic symptoms of acute cellular poisoning, such as that caused by cyanide. Sodium Thiosulfate Injection is indicated for use in the treatment of acute cyanide poisoning judged to be serious or life-threatening.

The medication is also applied across supportive oncology care to help manage the risk of long-term sensory deficits, such as irreversible hearing loss in pediatric patients undergoing cisplatin chemotherapy, and may assist in managing symptom clusters of complex conditions involving pathological mineral deposits like calciphylaxis. The therapeutic benefits include supportive management during phases of heightened systemic burden, helping to ease symptoms related to cardiovascular distress, and assisting with severe, chronic ischemic pain.

Quick Fact: Relief for Acute Systemic Stress and Chemotherapy-Related Sensory Risk

Brief Listing of Indications: The medication is used for managing the severe symptoms of acute cyanide poisoning, providing protective support against chemotherapy-induced hearing loss, easing the painful skin and vascular symptoms associated with calciphylaxis, and addressing the manifestation of discolored patches.

Regulatory References

1. Label: NITHIODOTE- sodium nitrite and sodium thiosulfate kit - DailyMed - NIH

Who Can and Cannot Use Sodium Thiosulfate?

The eligibility for using Sodium Thiosulfate (STS) is strictly defined by regulatory labeling and is dependent on the specific formulation and use (e.g., cyanide antidote versus ototoxicity prevention).

---

Contraindications and Prohibited Use

Population/Condition	Restriction
Severe Hypersensitivity	Contraindicated in patients with known severe allergy to STS or its components.
Infants (< 1 month)	Contraindicated for the ototoxicity prevention use due to risk of hypernatremia.
Elevated Serum Sodium	Use must be withheld if baseline serum sodium is greater than 145 mmol/L (for ototoxicity prevention).
Metastatic Cancer	Not recommended for the ototoxicity prevention indication.

---

Use Requiring Caution or Limitation

Use of STS requires caution and monitoring in patients with pre-existing conditions that affect electrolyte or renal balance, as STS is excreted by the kidneys. These conditions include renal impairment (kidney disease) and pre-existing hypernatremia.

Regarding Pregnancy, STS is generally placed in Pregnancy Category C; it is used only when the potential benefit outweighs the risk to the fetus, particularly in life-threatening situations like cyanide poisoning. Data regarding its presence in breast milk are limited, and use is generally avoided during lactation.

Interactions with other medicines and products

Official regulatory information for Sodium thiosulfate primarily addresses interactions based on chemical compatibility and administration timing, rather than extensive metabolic pathways. The following restrictions and requirements are documented in regulatory prescribing information.

---

Documented Interaction Restrictions

Interacting Substance	Restriction/Requirement	Official Classification
Cisplatin	Mandatory time separation of six hours after the completion of the Cisplatin infusion is required to avoid chemical interference that could reduce the antineoplastic agent’s intended efficacy.	Exposure-Modifying Interaction
Hydroxocobalamin	Must not be administered simultaneously in the same intravenous line due to documented chemical incompatibility.	Chemical Incompatibility
Other Cyanide Antidotes	Safety has not been formally established for co-administration with other antidotes, necessitating caution for combined use.	Use-with-Caution Interaction
CYP/Metabolic Enzymes	Formal drug interaction studies regarding common metabolic pathways, such as CYP enzymes, have not been conducted for the cyanide antidote preparation.	Absence of Documented Data

---

The regulatory profile is structured around these procedural and chemical constraints, reflecting the drug’s role in supportive and acute care settings. Furthermore, official labeling notes that the risk of adverse reactions may be greater in patients with impaired renal function, as the drug is substantially excreted by the kidney.

Sodium thiosulfate operates through distinct chemical interactions defined by its function as a specialized sulfur donor and chelating agent, affecting specific biological targets.

Enzyme-Facilitated Chemical Detoxification

The thiosulfate ion centers on the enzyme Rhodanese ( TST), located primarily in the mitochondria. By donating a sulfane sulfur atom, thiosulfate enables Rhodanese to rapidly catalyze the conversion of highly toxic CN^- into the non-toxic, excretable SCN^-. This mechanism immediately engages the trans-sulfuration pathway, which results in the restoration of Cytochrome oxidase (a3) activity.

Direct Inactivation and Mineral Disruption

Thiosulfate acts as a chelator, chemically binding to and inactivating reactive electrophilic chemical agents (e.g., active platinum complexes), thereby reducing the binding of platinum species to cellular macromolecules. Separately, this chemical property increases the solubility of pathological calcium phosphate mineral aggregates, facilitating the renal elimination of calcium complexes through increased solubility and altering the local crystallization environment.

Modulation of Cellular Stress Pathways

The compound exhibits chemical activity consistent with Reactive Oxygen Species (ROS) scavenging. Furthermore, it modulates localized signaling pathways by influencing sulfur species concentrations, which can affect pathways linked to Hydrogen Sulfide ( H2 S) and subsequently impact local redox dynamics.

Sodium thiosulfate is administered exclusively via the intravenous route as a sterile aqueous solution for its systemic applications, which include its use as an acute antidote and as a chemoprotectant. The dosing and administration frequency differ significantly between these official indications.

For the treatment of acute, life-threatening cyanide poisoning, sodium thiosulfate is administered as a single initial dose by slow intravenous injection, immediately following sodium nitrite. The standard adult dose is 12.5 grams (50 mL of a 25% solution). If signs of poisoning reappear, one-half of the original dose may be repeated. Pediatric dosing is based on body weight, with a dose of 1 mL/kg (250 mg/kg), not to exceed the adult dose, and is also administered sequentially. The time-critical nature of this use requires administration as early as possible after diagnosis.

As a protectant against cisplatin-induced ototoxicity in pediatric patients, a distinct formulation is used on a cyclic schedule tied to the chemotherapy course. The dose is determined by the patient's body surface area (BSA) according to actual body weight (ABW), ranging from 10 g/m^2 to 20 g/m^2. This dose is administered as an intravenous infusion over 15 minutes, starting precisely 6 hours after the cisplatin infusion is complete. A procedural constraint requires that the next cisplatin infusion must not begin in less than 10 hours following the sodium thiosulfate administration. The solution should not be co-administered in the same line with blood products or certain other medications.

Sodium Thiosulfate: Recent Clinical Evidence

Sodium thiosulfate (STS) is a compound that has been extensively studied for its ability to function as an antioxidant, sulfur donor, and chelating agent. Its clinical applications primarily focus on conditions related to heavy metal toxicity and calcification disorders, particularly those where few established treatment options exist.

---

Applications in Calciphylaxis

Research has concentrated on STS for treating calciphylaxis (Calcific Uremic Arteriolopathy), a severe and often fatal condition characterized by painful skin ulcers and calcification of small blood vessels. Multiple case series and small, non-randomized studies have investigated the use of intravenous STS. Evidence suggests that STS may influence the dissolution of calcified deposits, potentially due to its chelating properties and sulfur donation, which could contribute to a local antioxidant effect.

Initial findings from these observational studies reported an association between STS use and an improvement in pain, wound healing, and, in some cases, survival rates. However, due to the rarity of the condition and the limited size of available studies, the full mechanism of action and definitive efficacy remain under clinical investigation. Large-scale, randomized controlled trials are currently limited in this area.

---

Use in Cisplatin Toxicity

STS is an established therapy for neutralizing the effects of the chemotherapy agent cisplatin. It is often used to manage or prevent the drug's damaging effects on the kidneys (nephrotoxicity) following high-dose treatment. When administered rapidly after cisplatin, STS functions by binding to the remaining active cisplatin in the bloodstream, thereby reducing its toxicity to healthy tissues without significantly compromising its anti-cancer efficacy.

Other Investigational Uses

Research has explored the potential role of STS in treating other conditions, including cyanide poisoning and various forms of vascular calcification. In these areas, studies are generally preliminary, and clinical utility is not yet established.

Common questions about Sodium thiosulfate (FAQ)

---

Q: Why is Sodium thiosulfate sometimes used in patients with chronic kidney problems?

A: Studies and official information indicate that sodium thiosulfate is investigated for treating calciphylaxis, a rare, severe condition characterized by painful, calcified deposits. This condition is primarily seen in patients with end-stage kidney disease who are on dialysis. The compound is theorized to influence the solubility of calcium deposits, which may assist in their elimination from the body.

Q: How quickly does the effect of Sodium thiosulfate start after it is given?

A: Pharmacokinetic data from official sources describes how the medicine acts in the body. After the medicine is given intravenously, its concentration in the bloodstream begins to decline rapidly. The official information indicates that the concentration typically returns to pre-dose levels within three to six hours after administration.

Q: Why is Sodium thiosulfate administered through a vein (intravenously)?

A: According to the official product information, Sodium thiosulfate is administered intravenously because the medicine is poorly absorbed when taken by mouth. This route is necessary to achieve adequate blood concentration for the compound’s systemic protective and neutralizing actions.

Q: What are the signs of a possible allergic reaction to Sodium thiosulfate?

A: Regulatory documents state that signs of a severe allergic reaction (hypersensitivity) may occur. These signs can include a skin rash, hives, or itching. More serious signs involve swelling of the face, lips, or tongue, and trouble with breathing or wheezing.

Q: Does taking Sodium thiosulfate put strain on the liver?

A: Official pharmacokinetic studies indicate that Sodium thiosulfate is not metabolized by the main liver enzyme system (CYP enzymes). The medicine is instead substantially eliminated from the body by the kidneys. This indicates that the compound is primarily processed through the kidneys and has limited direct metabolic activity involving the liver.

Q: Are there long-term health concerns associated with Sodium thiosulfate use?

A: Long-term data themes regarding this drug's safety are available from post-hoc safety reviews. These analyses track patients, such as those in pediatric cancer trials, for periods exceeding three years.

Q: What are the potential effects of a fast infusion rate of the medicine?

A: Regulatory documents indicate that rapid infusion or overdose may lead to undesirable effects. These can include agitation, blurred vision, or muscle cramps. Due to the medicine's high concentration of sodium, rapid administration is associated with the potential for low blood pressure (hypotension).

Q: Can people with pre-existing heart conditions safely receive Sodium thiosulfate?

A: Official product labeling lists low blood pressure (hypotension) as an adverse reaction. Due to the medicine’s high sodium content, official information notes that the use of this drug in patients with pre-existing heart conditions necessitates careful supervision. Regulatory information confirms that monitoring is required during the administration process.

Q: Can people with a history of asthma be more sensitive to Sodium thiosulfate?

A: The drug's adverse reaction profile includes hypersensitivity (allergy). Regulatory sources cite this adverse reaction, and while the product label does not specifically detail asthma, caution is required, as hypersensitivity to related sulfur compounds may contribute to a worsening of asthma symptoms.

Q: Is it safe for older adults (the elderly) to receive Sodium thiosulfate?

A: Official regulatory information states that no specific dose adjustment is typically required for elderly patients aged 65 years and older. The absence of a required dose adjustment in official documents suggests that the standard dose established for adults is also applicable to older patients.

Q: What is the safety information about using Sodium thiosulfate for children older than one month?

A: Official product information confirms that this medicine is approved for use in children starting from one month of age. The approved indication is to reduce the risk of hearing loss (ototoxicity) caused by specific chemotherapy treatments.

Q: Is there research evidence supporting the use of Sodium thiosulfate for treating wounds or skin conditions?

A: Studies on Sodium thiosulfate related to skin effects are confined to its investigational use for calciphylaxis. This is a rare, severe condition characterized by painful, non-healing skin ulcers. The drug's official indications do not include the treatment of general wounds or other skin conditions.

Q: What is known about the effectiveness of Sodium thiosulfate for other types of poisoning besides cyanide?

A: Regulatory documents confirm that the medicine's established indication as an antidote is specifically for acute cyanide poisoning. Its effectiveness for treating other specific types of poisoning is generally not yet established or is still considered investigational.

Official Storage and Disposal Requirements

Sodium thiosulfate must be stored strictly according to the conditions outlined in regulatory labeling (FDA, EMA, USP) to maintain its stability.

Storage Component	Official Requirement
Temperature	Store at Controlled Room Temperature (20 C to 25 C), protecting from excessive heat.
Protection	Protect from light and moisture. Store away from acids and oxidizing agents.
Packaging	Keep the product in its container, which must be tightly closed when not in use.
Stability	The Solution for Injection is for single use only. Discard any unused portion immediately.
Disposal	Dispose of any unused medication, waste, and residues in accordance with local regulatory requirements. Do not dispose of the chemical substance into drains or water courses.